Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-26

Clinical Trial Update: Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients [Phase 2, Phase 3]

View source ↗

Summary

This document provides an update on a Phase 2/3 clinical trial evaluating simvastatin as a steroid-sparing treatment for uveitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SIMVASTATIN (SIMVASTATIN)

Snippet

Sponsor: University College, London | Conditions: Uveitis | Phase 2, Phase 3 | Status: UNKNOWN